142 related articles for article (PubMed ID: 34294276)
1. Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving Target.
Arcari L; Camastra G; Ciolina F; Danti M; Cacciotti L
J Am Coll Cardiol; 2021 Jul; 78(4):416-417. PubMed ID: 34294276
[No Abstract] [Full Text] [Related]
2. Reply: Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving Target.
Thavendiranathan P; Zhang L; Neilan TG
J Am Coll Cardiol; 2021 Jul; 78(4):417-418. PubMed ID: 34294277
[No Abstract] [Full Text] [Related]
3. Acute Myocarditis by Immune Checkpoint Inhibitor Identified by Quantitative Pixel-Wise Analysis of Native T1 Mapping.
Kato S; Fukui K; Kodama S; Azuma M; Nakayama N; Kishimoto M; Iwasawa T; Kimura K; Tamura K; Utsunomiya D
Circ Cardiovasc Imaging; 2021 May; 14(5):e012177. PubMed ID: 33951932
[No Abstract] [Full Text] [Related]
4. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
[No Abstract] [Full Text] [Related]
6. Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors.
Dougan M
Cancer Discov; 2023 May; 13(5):1040-1042. PubMed ID: 37139724
[TBL] [Abstract][Full Text] [Related]
7. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.
Zhang L; Zlotoff DA; Awadalla M; Mahmood SS; Nohria A; Hassan MZO; Thuny F; Zubiri L; Chen CL; Sullivan RJ; Alvi RM; Rokicki A; Murphy SP; Jones-O'Connor M; Heinzerling LM; Barac A; Forrestal BJ; Yang EH; Gupta D; Kirchberger MC; Shah SP; Rizvi MA; Sahni G; Mandawat A; Mahmoudi M; Ganatra S; Ederhy S; Zatarain-Nicolas E; Groarke JD; Tocchetti CG; Lyon AR; Thavendiranathan P; Cohen JV; Reynolds KL; Fradley MG; Neilan TG
Circulation; 2020 Jun; 141(24):2031-2034. PubMed ID: 32539614
[No Abstract] [Full Text] [Related]
8. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis.
Power JR; Alexandre J; Choudhary A; Ozbay B; Hayek S; Asnani A; Tamura Y; Aras M; Cautela J; Thuny F; Gilstrap L; Arangalage D; Ewer S; Huang S; Deswal A; Palaskas NL; Finke D; Lehman L; Ederhy S; Moslehi J; Salem JE;
Circulation; 2021 Nov; 144(18):1521-1523. PubMed ID: 34723640
[No Abstract] [Full Text] [Related]
9. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Doms J; Prior JO; Peters S; Obeid M
Ann Oncol; 2020 Sep; 31(9):1273-1275. PubMed ID: 32425357
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
Moslehi J; Lichtman AH; Sharpe AH; Galluzzi L; Kitsis RN
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33645548
[TBL] [Abstract][Full Text] [Related]
12. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance.
Sato T; Nakamori S; Watanabe S; Nishikawa K; Inoue T; Imanaka-Yoshida K; Ishida M; Sakuma H; Ito M; Dohi K
Circ Cardiovasc Imaging; 2020 Nov; 13(11):e010633. PubMed ID: 33153280
[No Abstract] [Full Text] [Related]
14. Diagnostic Value of the International Society of Cardio-Oncology Definition for Suspected Immune Checkpoint Inhibitor-Associated Myocarditis.
Deharo F; Thuny F; Cadour F; Resseguier N; Meilhac A; Gaubert M; Dolladille C; Paganelli F; Alexandre J; Cautela J
J Am Heart Assoc; 2023 Apr; 12(8):e029211. PubMed ID: 37042287
[No Abstract] [Full Text] [Related]
15. At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity.
Young A; Bluestone JA
Cancer Discov; 2021 Mar; 11(3):537-539. PubMed ID: 33653918
[TBL] [Abstract][Full Text] [Related]
16. Acute Myocarditis After Discontinuation of Immune Checkpoint Inhibitor Therapy.
Tamura Y; Tamura Y; Taniguchi H; Imanaka-Yoshida K
Circ J; 2023 Jan; 87(2):376. PubMed ID: 36310041
[No Abstract] [Full Text] [Related]
17. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.
Giblin GT; Dennehy C; Featherstone H; Clarke R; Murphy L; Timlin D; O'Keane C; Mulligan N; Kelly CM; Joyce E
Circ Heart Fail; 2021 Feb; 14(2):e007524. PubMed ID: 33478241
[No Abstract] [Full Text] [Related]
18. Fulminant myocarditis with myositis after treatment with immune checkpoint inhibitors.
González-Ferrero T; Vargas-Osorio K; González-Juanatey JR
Med Clin (Barc); 2022 Feb; 158(3):140-141. PubMed ID: 34294442
[No Abstract] [Full Text] [Related]
19. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
